FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 50
- Registration Number
- NCT00001764
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00004485
- Locations
- 🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.